Vir Biotechnology, Inc. (VIR) Stock Price & Analysis
Vir Biotechnology, Inc. (VIR) fell 6.96% to USD 8.69 as of July 25, 2026 at 06:40 UTC, according to Nexqual real-time market data.
VIR last closed at USD 9.34; the session ranged USD 8.62–9.14 on volume of 2,150,753 shares. Market capitalization is $1.47B, with a 52-week range of USD 4.16–11.66 (NMS). Source: Nexqual, July 25, 2026 at 06:40 UTC.
Key Statistics (as of July 25, 2026 at 06:40 UTC)
| Price | USD 8.69 |
|---|---|
| Change | ▼ 6.96% (down) |
| Previous Close | USD 9.34 |
| Open | USD 9 |
| Day Range | USD 8.62 – 9.14 |
| 52-Week Range | USD 4.16 – 11.66 |
| Volume | 2,150,753 shares |
| Market Cap | $1.47B |
| Exchange | NMS |
Technical Analysis (VIR)
Nexqual's technical model rates VIR "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.36 (neutral) |
| vs SMA50 | Below (USD 9.32) |
| MACD | -0.1 (negative) |
Analyst Ratings (VIR)
Wall Street analysts rate VIR "Strong Buy" based on 9 analysts, with a mean price target of USD 21.56 (range USD 16–30), per Nexqual as of July 25, 2026 at 06:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 21.56 |
| High Target | USD 30 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (VIR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.9 |
| Revenue Estimate | $222.57M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.85 vs est 0.48 ▼ miss |
| 2025-12-31 | USD -0.31 vs est -0.45 ▲ beat |
| 2025-09-30 | USD -1.17 vs est -0.86 ▼ miss |
| 2025-06-30 | USD -0.8 vs est -0.72 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
Financials & Fundamentals (VIR)
| Total Revenue | $65.50M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +459241.36% |
| Profit Margin | +0.00% |
| ROE | -47.69% |
| Debt / Equity | 11.76 |
| Current Ratio | 7.11 |
| Total Cash | $476.30M |
| Total Debt | $95.58M |
| Free Cash Flow | $-214.93M |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
Financial Health Score (VIR)
Nexqual rates Vir Biotechnology, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:40 UTC.
| Growth | Weak — Revenue -8% YoY (annual), declining |
|---|---|
| Profitability | Critical — Gross margin 0% |
| Balance Sheet | Strong — $476M cash vs $96M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$215M, burning cash |
| Efficiency | Critical — ROE -48%, ROA -24.8% |
Ownership (VIR)
| Insider Ownership | +6.59% |
|---|---|
| Institutional Ownership | +80.49% |
| Shares Outstanding | 168.65M |
| Float | 128.76M |
| Short % of Float | +11.08% |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
Leadership (VIR)
Vir Biotechnology, Inc. is led by Marianne De Backer M.B.A., M.Sc. (age 56), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:40 UTC.
| President, CEO & Director | Marianne De Backer M.B.A., M.Sc. (age 56) |
|---|---|
| Executive VP & CFO | Jason O'Byrne (age 56) |
| Executive VP & Chief Scientific Officer | Jennifer Eileen Towne |
| Senior Vice President of Corporate Communications | Carolyn Wang |
Major Backers & Investors (VIR)
Notable institutional backers of Vir Biotechnology, Inc. include Arch Venture Management, Llc, SB Investment Advisers (UK) LTD, GSK plc, according to Nexqual as of July 25, 2026 at 06:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Arch Venture Management, Llc | 7.66% |
| SB Investment Advisers (UK) LTD | 6.49% |
| GSK plc | 5.07% |
| Goldman Sachs | 1.93% |
| Morgan Stanley | 1.69% |
| Adar1 Capital Management, LLC | 1.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.62% |
| Vanguard Group | 15.21% |
| State Street | 7.81% |
Source: Nexqual, July 25, 2026 at 06:40 UTC.
From Vir Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- We will receive $335 million in upfront and near-term milestone payments, including $240 million in cash, a $75 million equity investment pursuant to a separate Stock Purchase Agreement (the Astellas SPA, described further below), and a near-term $20 million milestone payment upon completion of manufacturing technology transfer, anticipated in the second quarter or third quarter of 2027.
- We use our world-class capabilities in antibody discovery and engineering, coupled with our proprietary AI engine dAIsY ™ system, and the PRO-XTEN ® masking platform, to quickly and effectively discover and optimize potential new medicines.
- Tobevibart was identified using our proprietary antibody discovery platform.
- Our platform has been successfully applied to identify mAbs for multiple pathogens including SARS-CoV-2, HBV, HDV, Ebola virus, and HIV.
Partnerships
- In connection with the 2021 GSK Agreement, we entered into a stock purchase agreement with GGL pursuant to which we issued 1,924,927 shares of our common stock to GGL for an aggregate purchase price of approximately $120.0 million.
- Concurrently with the execution of the Astellas Agreement, we have also entered into the Astellas SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of our common stock for an aggregate purchase price of approximately $75 million, subject to customary closing conditions and the closing of the Astellas Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | USD 2.1 | ▼ 7.89% |
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 4.17% |
| INO | Inovio Pharmaceuticals, Inc. | USD 0.97 | ▼ 8.49% |
| BNTX | BioNTech SE | USD 89.33 | ▼ 2.72% |
| ARCT | Arcturus Therapeutics Holdings | USD 5.53 | ▼ 6.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:40 UTC. This page is informational and not investment advice.